MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 125671 | Name: DOTA-LM3
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

DOTA-LM3 is a somatostatin receptor ( SSTR ) antagonist.

Chemical Structure

DOTA-LM3
DOTA-LM3
CAS#1192362-32-5

Theoretical Analysis

MedKoo Cat#: 125671

Name: DOTA-LM3

CAS#: 1192362-32-5

Chemical Formula: C69H93ClN16O19S2

Exact Mass: 1548.5900

Molecular Weight: 1550.17

Elemental Analysis: C, 53.46; H, 6.05; Cl, 2.29; N, 14.46; O, 19.61; S, 4.14

Price and Availability

Size Price Availability Quantity
10mg USD 1,250.00 2 Weeks
50mg USD 2,050.00 2 Weeks
100mg USD 3,850.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
DOTA-LM3; DOTALM3; DOTA LM3
IUPAC/Chemical Name
2,2',2''-(10-(2-((1-((4-((1-amino-3-(4-hydroxyphenyl)-1-oxopropan-2-yl)carbamoyl)-10-(4-aminobutyl)-16-(4-hydroxybenzyl)-7-(1-hydroxyethyl)-6,9,12,15,18-pentaoxo-13-(4-ureidobenzyl)-1,2-dithia-5,8,11,14,17-pentaazacycloicosan-19-yl)amino)-3-(4-chlorophenyl)-1-oxopropan-2-yl)amino)-2-oxoethyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetic acid
InChi Key
KOZHSMBONUANKJ-UHFFFAOYSA-N
InChi Code
InChI=1S/C69H93ClN16O19S2/c1-40(87)60-68(104)81-55(66(102)77-50(61(72)97)30-43-9-17-47(88)18-10-43)39-107-106-38-54(67(103)79-53(33-44-11-19-48(89)20-12-44)65(101)78-52(32-42-7-15-46(16-8-42)74-69(73)105)64(100)76-49(62(98)82-60)4-2-3-21-71)80-63(99)51(31-41-5-13-45(70)14-6-41)75-56(90)34-83-22-24-84(35-57(91)92)26-28-86(37-59(95)96)29-27-85(25-23-83)36-58(93)94/h5-20,40,49-55,60,87-89H,2-4,21-39,71H2,1H3,(H2,72,97)(H,75,90)(H,76,100)(H,77,102)(H,78,101)(H,79,103)(H,80,99)(H,81,104)(H,82,98)(H,91,92)(H,93,94)(H,95,96)(H3,73,74,105)
SMILES Code
CC(C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CC=C(C=C2)NC(=O)N)CC3=CC=C(C=C3)O)NC(=O)C(CC4=CC=C(C=C4)Cl)NC(=O)CN5CCN(CCN(CCN(CC5)CC(=O)O)CC(=O)O)CC(=O)O)C(=O)NC(CC6=CC=C(C=C6)O)C(=O)N)O
Appearance
To be determined
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 -4 C for short term (days to weeks) or -20 C for long term(months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 1,550.17 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Zhu W, Jia R, Yang Q, Cheng Y, Zhao H, Bai C, Xu J, Yao S, Huo L. A prospective randomized, double-blind study to evaluate the diagnostic efficacy of 68Ga-NODAGA-LM3 and 68Ga-DOTA-LM3 in patients with well-differentiated neuroendocrine tumors: compared with 68Ga- DOTATATE. Eur J Nucl Med Mol Imaging. 2022 Apr;49(5):1613-1622. doi: 10.1007/s00259-021-05512-y. Epub 2021 Dec 7. PMID: 34874478. 2: Zhu W, Cheng Y, Jia R, Zhao H, Bai C, Xu J, Yao S, Huo L. A Prospective, Randomized, Double-Blind Study to Evaluate the Safety, Biodistribution, and Dosimetry of 68Ga-NODAGA-LM3 and 68Ga-DOTA-LM3 in Patients with Well-Differentiated Neuroendocrine Tumors. J Nucl Med. 2021 Oct;62(10):1398-1405. doi: 10.2967/jnumed.120.253096. Epub 2021 Feb 12. PMID: 33579804; PMCID: PMC8724897. 3: Severin GW, Kristensen LK, Nielsen CH, Fonslet J, Jensen AI, Frellsen AF, Jensen KM, Elema DR, Maecke H, Kjær A, Johnston K, Köster U. Neodymium-140 DOTA- LM3: Evaluation of an In Vivo Generator for PET with a Non-Internalizing Vector. Front Med (Lausanne). 2017 Jul 12;4:98. doi: 10.3389/fmed.2017.00098. PMID: 28748183; PMCID: PMC5506079. 4: Borgna F, Haller S, Rodriguez JMM, Ginj M, Grundler PV, Zeevaart JR, Köster U, Schibli R, van der Meulen NP, Müller C. Combination of terbium-161 with somatostatin receptor antagonists-a potential paradigm shift for the treatment of neuroendocrine neoplasms. Eur J Nucl Med Mol Imaging. 2022 Mar;49(4):1113-1126. doi: 10.1007/s00259-021-05564-0. Epub 2021 Oct 8. PMID: 34625828; PMCID: PMC8921065. 5: Borgna F, Barritt P, Grundler PV, Talip Z, Cohrs S, Zeevaart JR, Köster U, Schibli R, van der Meulen NP, Müller C. Simultaneous Visualization of 161Tb- and 177Lu-Labeled Somatostatin Analogues Using Dual-Isotope SPECT Imaging. Pharmaceutics. 2021 Apr 12;13(4):536. doi: 10.3390/pharmaceutics13040536. PMID: 33921467; PMCID: PMC8070648.